Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

被引:352
作者
Platten, M [1 ]
Ho, PP
Youssef, S
Fontoura, P
Garren, H
Hur, EM
Gupta, R
Lee, LY
Kidd, BA
Robinson, WH
Sobel, RA
Selley, ML
Steinman, L
机构
[1] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol Neuropathol, Stanford, CA 94305 USA
[3] Univ Tubingen, Dept Gen Neurol, D-72076 Tubingen, Germany
[4] Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany
[5] Univ Nova Lisboa, Fac Med Sci, Dept Immunol, P-1169056 Lisbon, Portugal
[6] Bayhill Therapeut Inc, Palo Alto, CA 94303 USA
[7] Vet Affairs Hlth Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA
[8] Angiogen Pharmaceut Pty Ltd, Sydney, NSW 2000, Australia
关键词
D O I
10.1126/science.1117634
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Local catabolism of, the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase ([DO) is considered an important mechanism of regulating T cell immunity. We show that IDO transcription was increased when myelin-specific T cells were stimulated with tolerogenic altered self-peptides. Catabolites of Trp suppressed proliferation of myelin-specific T cells and inhibited production of proinflammatory T helper-1 (T(H)1) cytokines. N-(3,4,-Dimethoxycinnamoyl) anthranilic acid (3,4-DAA), an orally active syntihetic derivative of the Trp metabolite anthranilic acid, reversed paralysis in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS). Trp catabolites and their derivatives offer a new strategy for treating T(H)1-mediated autoimmune diseases such as MS.
引用
收藏
页码:850 / 855
页数:6
相关论文
共 30 条
  • [1] A road map for those who don't know JAK-STAT
    Aaronson, DS
    Horvath, CM
    [J]. SCIENCE, 2002, 296 (5573) : 1653 - 1655
  • [2] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
    Bielekova, B
    Goodwin, B
    Richert, N
    Cortese, I
    Kondo, T
    Afshar, G
    Gran, B
    Eaton, J
    Antel, J
    Frank, JA
    McFarland, HF
    Martin, R
    [J]. NATURE MEDICINE, 2000, 6 (10) : 1167 - 1175
  • [3] Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
    Brocke, S
    Gijbels, K
    Allegretta, M
    Ferber, I
    Piercy, C
    Blankenstein, T
    Martin, R
    Utz, U
    Karin, N
    Mitchell, D
    Veromaa, T
    Waisman, A
    Gaur, A
    Conlon, P
    Ling, N
    Fairchild, PJ
    Wraith, DC
    OGarra, A
    Fathman, CG
    Steinman, L
    [J]. NATURE, 1996, 379 (6563) : 343 - 346
  • [4] The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses
    Carreno, BM
    Collins, M
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 : 29 - 53
  • [5] Microglia as liaisons between the immune and central nervous systems: Functional implications for multiple sclerosis
    Carson, MJ
    [J]. GLIA, 2002, 40 (02) : 218 - 231
  • [6] Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
    Duda, PW
    Schmied, MC
    Cook, SL
    Krieger, JI
    Hafler, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) : 967 - 976
  • [7] TICKLING THE TCR - SELECTIVE T-CELL FUNCTIONS STIMULATED BY ALTERED PEPTIDE LIGANDS
    EVAVOLD, BD
    SLOANLANCASTER, J
    ALLEN, PM
    [J]. IMMUNOLOGY TODAY, 1993, 14 (12): : 602 - 609
  • [8] Design of effective immunotherapy for human autoimmunity
    Feldmann, M
    Steinman, L
    [J]. NATURE, 2005, 435 (7042) : 612 - 619
  • [9] Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
    Frumento, G
    Rotondo, R
    Tonetti, M
    Damonte, G
    Benatti, U
    Ferrara, GB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (04) : 459 - 468
  • [10] Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway
    Garren, H
    Ruiz, PJ
    Watkins, TA
    Fontoura, P
    Nguyen, LVT
    Estline, ER
    Hirschberg, DL
    Steinman, L
    [J]. IMMUNITY, 2001, 15 (01) : 15 - 22